Press release
Dup15q Syndrome market is expected to reach USD 240 million by 2034
Dup15q Syndrome
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71935
The disorder has gained increasing recognition due to advances in genetic testing, growing awareness among clinicians, and active patient advocacy groups. While no disease-modifying therapies currently exist, management focuses on seizure control, behavioral therapies, and supportive interventions. Research into gene-targeted therapies, antisense oligonucleotides (ASOs), and precision medicine is beginning to expand opportunities in this rare disease market.
Market Overview
• Market Size (2024): USD 120 million
• Forecast (2034): USD 240 million
• CAGR (2025-2034): 7.0%
Growth is supported by expanded newborn genetic testing, rising epilepsy treatment demand, and pipeline precision therapies.
Key Highlights:
• Prevalence estimated at 1 in 20,000 live births, but underdiagnosis remains significant.
• Epilepsy affects over 60% of Dup15q patients, often resistant to conventional drugs.
• Genetic testing advances are enabling earlier and more accurate diagnosis.
• Orphan drug incentives driving pipeline research into rare neurodevelopmental disorders.
Segmentation Analysis
By Product Type:
• Pharmacological Therapies (Symptomatic)
o Anti-Seizure Medications (Valproate, Clobazam, Lamotrigine, Cannabidiol)
o Antipsychotics & Behavioral Medications (for aggression, irritability)
o Sleep Aids and Anxiety Medications
o Pipeline Therapies (ASOs, gene therapy, novel anti-epileptics)
• Non-Pharmacological Therapies
o Applied Behavioral Analysis (ABA)
o Speech, Occupational, and Physical Therapy
o Educational & Social Support Programs
• Diagnostics
o Chromosomal Microarray (CMA)
o FISH (Fluorescence in situ Hybridization)
o Next-Generation Sequencing (NGS) Panels
o Prenatal Genetic Testing
By Platform:
• Small Molecules (anti-seizure drugs, psychotropics)
• Biologics (ASOs, gene therapies - pipeline)
• Genetic Testing & Diagnostics
• Digital Therapeutics (behavioral therapy support apps)
By Technology:
• Next-Generation Sequencing (NGS)
• ASO Technology Platforms
• AI-Enhanced Genetic Data Interpretation
• Digital Neurodevelopmental Tools
By End Use:
• Hospitals & Pediatric Neurology Clinics
• Genetic Testing Laboratories
• Specialty Epilepsy Centers
• Research Institutes
By Application:
• Epilepsy & Seizure Management
• Autism Spectrum Disorder Symptoms
• Developmental Delay & Intellectual Disability
• Clinical Research
Segmentation Summary:
Anti-seizure drugs dominate current care, but genetic diagnostics and ASO-based therapies are the fastest-growing segments. Multidisciplinary care combining pharma, behavioral, and educational interventions defines the market.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71935/dup15q-syndrome-market
Regional Analysis
North America
• ~48% share in 2024.
• Strong genetic testing adoption and orphan drug incentives.
• Active patient advocacy groups like Dup15q Alliance.
Europe
• ~28% share.
• Germany, UK, and France leading rare disease genetic testing adoption.
• EMA supporting orphan drug pipelines.
Asia-Pacific
• Fastest-growing region with CAGR of ~8.0%.
• Rising pediatric neurology infrastructure in Japan, China, and India.
• Expanding newborn genetic testing programs.
Middle East & Africa
• Limited rare disease infrastructure, smaller market share.
• Gradual expansion of genetic diagnostics.
Latin America
• Brazil and Mexico leading rare disease awareness initiatives.
• Increasing availability of genetic counseling and testing.
Regional Summary:
North America and Europe dominate due to advanced infrastructure and orphan drug policies, while Asia-Pacific grows fastest due to rising healthcare investments and genetic testing expansion.
Market Dynamics
Key Growth Drivers:
• Rising adoption of genetic testing and early diagnosis.
• Growing epilepsy treatment demand in Dup15q patients.
• Orphan drug incentives boosting pipeline innovation.
• Strong advocacy group involvement increasing awareness.
Key Challenges:
• Lack of disease-modifying therapies.
• Small patient population limits clinical trial feasibility.
• High cost of genetic testing and precision therapies.
• Limited specialized care centers in low-resource regions.
Latest Trends:
• Development of ASOs and gene therapy platforms for rare neurodevelopmental disorders.
• Expansion of digital tools for behavioral therapy support.
• Integration of NGS panels in newborn screening programs.
• Increased patient advocacy collaborations with biotech firms.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71935
Competitor Analysis
Major Players in the Market:
• Ovid Therapeutics Inc.
• Ultragenyx Pharmaceutical Inc.
• Biogen Inc.
• Roche Holding AG
• Novartis AG
• Pfizer Inc.
• Ionis Pharmaceuticals, Inc. (ASO platform)
• Sarepta Therapeutics (gene therapy research)
• Thermo Fisher Scientific Inc. (genetic testing tools)
• Invitae Corporation (genetic diagnostics)
Competitive Summary:
Ovid, Ultragenyx, and Biogen are active in rare disease drug pipelines, with Ionis and Sarepta driving ASO and gene therapy innovation. Roche, Novartis, and Pfizer maintain broad CNS portfolios. Thermo Fisher and Invitae dominate diagnostics. Competition focuses on genetic diagnostics, pipeline gene therapies, and orphan drug development.
Conclusion
The Dup15q Syndrome Market, valued at USD 120 million in 2024, is projected to reach USD 240 million by 2034, growing at a CAGR of 7.0%. Genetic testing adoption, epilepsy treatment demand, and pipeline precision therapies will shape the future.
Key Takeaways:
• Anti-seizure medications dominate care today, but gene-targeted therapies are emerging.
• North America and Europe lead, while Asia-Pacific grows fastest.
• NGS and ASO-based precision medicine represent major breakthroughs.
• Advocacy-driven awareness programs accelerating diagnosis and research funding.
The next decade will transform Dup15q care from symptomatic seizure management to precision-driven, genetic-based therapies, creating opportunities for pharma, biotech, diagnostics, and digital health innovators.
This report is also available in the following languages : Japanese (重複15q症候群市場), Korean (Dup15q 증후군 시장), Chinese (Dup15q综合征市场), French (Marché du syndrome Dup15q), German (Markt für das Dup15q-Syndrom), and Italian (Mercato della sindrome dup15q), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71935/dup15q-syndrome-market#request-a-sample
Our More Reports:
Neuropathic Ocular Pain (NOP)-Market Insights, Epidemiology, and Market
https://exactitudeconsultancy.com/reports/72288/neuropathic-ocular-pain-nop-market
Hyperopia Market
https://exactitudeconsultancy.com/reports/72287/hyperopia-market
Granulomatosis With Polyangiitis - Market
https://exactitudeconsultancy.com/reports/72286/granulomatosis-with-polyangiitis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dup15q Syndrome market is expected to reach USD 240 million by 2034 here
News-ID: 4180916 • Views: …
More Releases from Exactitude Consultancy
Drug-Induced Dyskinesia Market Detailed Industry Report Analysis 2025-2034
Introduction
Drug-induced dyskinesia (DID) is one of the most challenging side effects associated with long-term use of dopaminergic therapies, especially in Parkinson's disease management. Characterized by involuntary, erratic movements, DID significantly impacts quality of life and treatment adherence. Over the past decade, increasing awareness among physicians and patients, coupled with ongoing advancements in neuropharmacology, has placed the drug-induced dyskinesia market in the spotlight. With an aging population, rising prevalence of neurological…
Encephalitis Market is expected to reach USD 3.5 billion by 2034
Encephalitis Market Outlook 2024-2034: Expanding Diagnostics, Antiviral Therapies, and Global Awareness
Introduction
Encephalitis is an inflammation of the brain tissue caused by viral, bacterial, autoimmune, or idiopathic factors. It can lead to fever, seizures, confusion, memory loss, and long-term neurological complications. The condition is a serious medical emergency requiring immediate hospitalization and intensive care.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71937
The most common viral causes include Herpes Simplex Virus (HSV),…
Horner's Syndrome Market is expected to reach USD 1.1 billion by 2034
Horner's syndrome is a rare neurological condition caused by disruption of the sympathetic nerves supplying the eye and facial region. It is characterized by ptosis (drooping eyelid), miosis (constricted pupil), anhidrosis (reduced sweating), and enophthalmos (sunken eye appearance).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71939
The disorder can result from stroke, tumors (lung apex, brainstem), spinal cord injuries, vascular abnormalities (carotid artery dissection), or trauma. While Horner's syndrome itself…
Infantile Spasm Market is expected to reach USD 590 million by 2034
Infantile spasms (IS), also known as West syndrome, is a rare but severe epileptic encephalopathy that typically presents in infants aged 3-12 months. The condition is characterized by sudden spasms, hypsarrhythmia on EEG, and developmental regression. IS has a profound long-term impact, with many children developing intellectual disability, autism spectrum disorder, or refractory epilepsy.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71941
The global market is expanding due to growing…
More Releases for Dup15q
Dup15q syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Ovid …
Dup15q syndrome therapies, such as Bexicaserin, UBE3A (ASO), and others, are expected to boost the Dup15q syndrome Market in the upcoming years.
DelveInsight has launched a new report on "Dup15q syndrome - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Dup15q syndrome, historical and forecasted epidemiology as well as the Dup15q syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom)…
Dup15q Syndrome Market Expected to rise, 2032 | Ovid Therapeutics, Takeda, Q-Sta …
The Dup15q Syndrome market growth is driven by factors like increase in the prevalence of Dup15q Syndrome, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Dup15q Syndrome market report [https://www.delveinsight.com/report-store/dup15q-syndrome-market-forecast?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Dup15q Syndrome market size, share, Dup15q Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and…
Dup15q Syndrome Drugs Market Size Report 2032 | Ovid Therapeutics, Takeda, Q-Sta …
DelveInsight's "Dup15q Syndrome Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the Dup15q Syndrome, historical and forecasted epidemiology as well as the Dup15q Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Dup15q Syndrome Market with DelveInsight's In-Depth Report @ Dup15q Syndrome Market Size- https://www.delveinsight.com/sample-request/dup15q-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
Dup15q Syndrome Therapeutics Market Size in the 7MM is expected to grow by 2034, …
DelveInsight's "Dup15q Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Dup15q Syndrome, historical and forecasted epidemiology as well as the Dup15q Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Dup15q Syndrome Market by downloading the comprehensive report from DelveInsight @ Dup15q Syndrome Treatment Market Size- https://www.delveinsight.com/sample-request/dup15q-syndrome-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…
Dup15q Syndrome Market Size in the 7MM is expected to grow by 2032, estimates De …
Dup15q Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Dup15q Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Dup15q Syndrome Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the Dup15q Syndrome, historical and forecasted…
Dup15q Syndrome Treatment Market Size, Treatment Drugs, and Companies 2024
Dup15q Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Dup15q Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Dup15q Syndrome Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Dup15q Syndrome, historical and…
